Bristol Myers Squibb, through its RayzeBio subsidiary, acquired global rights to Philochem AG’s OncoACP3, a radiopharmaceutical candidate for prostate cancer, with a $350 million upfront payment plus milestone potentials. The program represents an addition to BMS’s growing radiopharmaceutical segment, following its $4.1 billion acquisition of RayzeBio. This strategic expansion underlines BMS's commitment to oncology innovations integrating diagnostics and therapeutics targeting prostate malignancies.